AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19921355 — intervention group
Group type: COMPARATOR
Intervention: ketamine-desflurane (KD)
Number of subjects: 280
Study 19921355 — intervention group
Group type: COMPARATOR
Intervention: ketamine-sevoflurane (KS)
Number of subjects: 280
Study 19921355 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam-propofol (MP)
Number of subjects: 280
Study 19921355 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam-remifentanil (MR)
Number of subjects: 280
Study 19921355 — intervention group
Group type: COMPARATOR
Intervention: midazolam-desflurane (MD)
Number of subjects: 280
Study 19921355 — intervention group
Group type: COMPARATOR
Intervention: midazolam-sevoflurane (MS)
Number of subjects: 280
Study 16953834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 61
Study 16953834 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Alternative
Number of subjects: 61
Study 15225171 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 0
Study 15225171 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 0
Study 15225171 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen 800 mg three-times daily
Number of subjects: 0
Study 11291429 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce STD recurrence
Number of subjects: 617
Study 11291429 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment for sexual abuse in programs focusing on STD/HIV prevention
Number of subjects: 617
Study 9198491 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml Gd-DTPA with three successive acquisitions at fixed intervals (25, 53 and 81 s)
Number of subjects: 50
Study 9198491 — intervention group
Group type: COMPARATOR
Intervention: 20 ml Gd-DTPA with individually determined MR acquisition start based on prior evaluation of contrast material transit times
Number of subjects: 50
Study 8234106 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 14
Study 8234106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3302917 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 60
Study 3302917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus sisomicin (C/S)
Number of subjects: 60
Study 3302917 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus sisomicin
Number of subjects: 60
Study 31787108 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine initiated in the community (N=107)
Number of subjects: 211
Study 31787108 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine initiated in prison (N=106)
Number of subjects: 211
Study 28939185 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (glue) skin adhesive
Number of subjects: 409
Study 28939185 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic ointment
Number of subjects: 409
Study 28939185 — intervention group
Group type: COMPARATOR
Intervention: Both groups (glue and antibiotic ointment)
Number of subjects: 409
Study 26438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + saline
Number of subjects: 58
Study 26438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + remifentanil (5 ng.mL(‐1))
Number of subjects: 58
Study 23538911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training for 2 weeks
Number of subjects: 0
Study 21743398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachment
Number of subjects: 36
Study 21743398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar attachment
Number of subjects: 36
Study 21743398 — intervention group
Group type: COMPARATOR
Intervention: Locator attachment
Number of subjects: 36
Study 21743398 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 36
Study 21743398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostheses
Number of subjects: 36
Study 19739696 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (6-12 mg twice daily)
Number of subjects: 473
Study 19739696 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 473
Study 19739696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 19739696 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 473
Study 18447059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0
Study 15386823 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 12
Study 15386823 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 12
Study 12040346 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 or 60 mg given every 12 hours for 14 days)
Number of subjects: 1102
Study 12040346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102
Study 12040346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice daily for 14 days)
Number of subjects: 1102
Study 9672165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with alpha-interferon and lamivudine for 16 weeks
Number of subjects: 20
Study 7729237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 500 mg/day, administered seven to nine hours after awakening (R x 2)
Number of subjects: 55
Study 7729237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) 500 mg/day, administered within two hours of awakening (R x 1)
Number of subjects: 55
Study 7729237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) 500 mg/day, administered within two hours before bedtime (R x 3)
Number of subjects: 55
Study 2686410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg every 12 hours intravenously, then oral)
Number of subjects: 80
Study 2686410 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (1 to 2 g intravenously every eight to 12 hours)
Number of subjects: 80
Study 1105632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 12
Study 1105632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31120118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (oral factor Xa inhibitor) given at the approved dose for PE for ≥3 months
Number of subjects: 525
Study 31120118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (oral factor Xa inhibitor)
Number of subjects: 525
Study 31507265 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) based intervention on infant immunisation
Number of subjects: 1223
Study 28099372 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated learning experiences
Number of subjects: 0
Study 28099372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practicum learning experiences
Number of subjects: 0
Study 28099372 — intervention group
Group type: EXPERIMENTAL
Intervention: Final simulated experience
Number of subjects: 0
Study 25688780 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily for 24 weeks)
Number of subjects: 1510
Study 25688780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1510
Study 23042475 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis of 0.4% Dex‐P
Number of subjects: 34
Study 23042475 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis of 0.4% Dex‐P
Number of subjects: 34
Study 21957245 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in field B followed by training in field A (or washout)
Number of subjects: 0
Study 21957245 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding reinforcement for the current motor output
Number of subjects: 0
Study 21957245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation followed by washout or reverse adaptation
Number of subjects: 0
Study 21957245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of reinforcement
Number of subjects: 0
Study 19100570 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon with nephrectomy
Number of subjects: 241
Study 19100570 — intervention group
Group type: COMPARATOR
Intervention: Interferon without nephrectomy
Number of subjects: 241
Study 19100570 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status 1 vs 0
Number of subjects: 241
Study 19100570 — intervention group
Group type: EXPERIMENTAL
Intervention: High alkaline phosphatase
Number of subjects: 241
Study 19100570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung metastasis only
Number of subjects: 241
Study 19100570 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progressive disease within 90 days (in subset surviving at least 90 days)
Number of subjects: 241
Study 19100570 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status (in subset surviving at least 90 days)
Number of subjects: 241
Study 16287132 — intervention group
Group type: EXPERIMENTAL
Intervention: BNS (nutrition support delivered before treatment)
Number of subjects: 1073
Study 16287132 — intervention group
Group type: EXPERIMENTAL
Intervention: BNS
Number of subjects: 1073
Study 16287132 — intervention group
Group type: COMPARATOR
Intervention: TNS (nutrition support delivered during treatment)
Number of subjects: 1073
Study 16287132 — intervention group
Group type: COMPARATOR
Intervention: No NS (no nutrition support)
Number of subjects: 1073
Study 16287132 — intervention group
Group type: COMPARATOR
Intervention: TNS
Number of subjects: 1073
Study 16287132 — intervention group
Group type: COMPARATOR
Intervention: No NS
Number of subjects: 1073
Study 15230999 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with Ca
Number of subjects: 757
Study 15230999 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with Ca and cholecalciferol (5 or 8 microg)
Number of subjects: 757
Study 15230999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no milk intervention)
Number of subjects: 757
Study 11162750 — intervention group
Group type: EXPERIMENTAL
Intervention: adjunctive remacemide hydrochloride 150 mg q.i.d. for 4 weeks
Number of subjects: 28
Study 11162750 — intervention group
Group type: EXPERIMENTAL
Intervention: adjunctive remacemide hydrochloride
Number of subjects: 28
Study 11162750 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 9057729 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (0.15-0.2 g/kg bodyweight, monthly for 2 years)
Number of subjects: 150
Study 9057729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8392903 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 10 micrograms/kg on days 4 to 14
Number of subjects: 41
Study 8392903 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin starting from 45 mg/m2 every 3 weeks for six courses (Group A)
Number of subjects: 41
Study 8392903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin with GM-CSF priming from day -17 to -7 (Group C)
Number of subjects: 41
Study 4004191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (250 mg + 125 mg) three times daily for 7 days
Number of subjects: 80
Study 4004191 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (250 mg) three times daily for 7 days
Number of subjects: 80
Study 4004191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (for ampicillin-resistant strains)
Number of subjects: 80
Study 4004191 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (for ampicillin-resistant strains)
Number of subjects: 80
Study 30807663 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK561679 350 mg/day for 6 weeks
Number of subjects: 47
Study 30807663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30029620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered in the community without an SMS reminder
Number of subjects: 75
Study 30029620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered in the community with an SMS reminder
Number of subjects: 75
Study 30029620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered in the community with a community health worker reminder
Number of subjects: 75
Study 30029620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered at the hospital with an SMS reminder
Number of subjects: 75
Study 30029620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered at the hospital without an SMS reminder
Number of subjects: 75
Study 26763023 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Self‐Management Program
Number of subjects: 143
Study 26763023 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford chronic condition self‐management program
Number of subjects: 143
Study 26763023 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 143
Study 26763023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 143
Study 26763023 — intervention group
Group type: EXPERIMENTAL
Intervention: Global disability
Number of subjects: 143
Study 24985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic management targeting HbA1c <6.0% for 4.0 ± 1.2 years
Number of subjects: 4119
Study 24985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transition HbA1c <6.5%
Number of subjects: 4119
Study 24985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower pre-transition HbA1c levels
Number of subjects: 4119
Study 24985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 4119
Study 22177371 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg once daily
Number of subjects: 641
Study 22177371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 16198885 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (LAVI > 34 mL/m2)
Number of subjects: 104
Study 11939420 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led group
Number of subjects: 42
Study 11939420 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 11939420 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led group
Number of subjects: 42
Study 11477904 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of tetramethylpyrazine (TMP) dripped intravenously after anesthesia and 1 mg/kg of TMP infused into oxygenator after CPB
Number of subjects: 30
Study 11477904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TMP treatment)
Number of subjects: 30
Study 7657041 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 353
Study 7657041 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every other day
Number of subjects: 353
Study 7657041 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg on weekends
Number of subjects: 353
Study 2784977 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol continuous infusion for 3 days
Number of subjects: 0
Study 2784977 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation
Number of subjects: 0
Study 68331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol plus isoniazid (E+I)
Number of subjects: 126
Study 68331 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin plus isoniazid (R+I)
Number of subjects: 126
Study 29188268 — intervention group
Group type: EXPERIMENTAL
Intervention: AQoL-8D
Number of subjects: 164
Study 29188268 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-M
Number of subjects: 164
Study 27498098 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS (specialist depression services)
Number of subjects: 307
Study 27498098 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 307
Study 25299799 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270
Number of subjects: 80
Study 25299799 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 350
Number of subjects: 80
Study 23848972 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 24779
Study 20121889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplement (4 g/day, n = 49)
Number of subjects: 97
Study 20121889 — intervention group
Group type: COMPARATOR
Intervention: Olive-oil (placebo, n = 48)
Number of subjects: 97
Study 17956874 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1572
Study 17956874 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase (fibrinolysis)
Number of subjects: 1572
Study 17956874 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients transferred to angioplasty
Number of subjects: 1572
Study 17956874 — intervention group
Group type: COMPARATOR
Intervention: On-site fibrinolysis
Number of subjects: 1572
Study 17956874 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study 16832794 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention of screening for melanoma, including community education program, education program for medical practitioners, and dedicated skin-screening clinics.
Number of subjects: 3355
Study 16832794 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention of screening for melanoma.
Number of subjects: 3355
Study 12804125 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (various doses)
Number of subjects: 0
Study 12804125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10907148 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-exposed couples (observed parental violence by male partner)
Number of subjects: 71
Study 10907148 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-exposed couples (observed parental violence by female partner)
Number of subjects: 71
Study 10907148 — intervention group
Group type: COMPARATOR
Intervention: Unexposed couples (neither partner observed parental violence)
Number of subjects: 71
Study 10907148 — intervention group
Group type: COMPARATOR
Intervention: Unexposed couples
Number of subjects: 71
Study 8985794 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise at 30 Watts
Number of subjects: 20
Study 8985794 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg exercise at 30 Watts
Number of subjects: 20
Study 8985794 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak arm exercise
Number of subjects: 20
Study 8985794 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak leg exercise
Number of subjects: 20
Study 8985794 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 age-matched healthy subjects)
Number of subjects: 20
Study 1615479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomoparan (Org 10172) 750 anti-factor Xa units, s.c., b.i.d. for 10 days
Number of subjects: 197
Study 1615479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 1615479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomoparan (Org 10172)
Number of subjects: 197
Study 6333182 — intervention group
Group type: COMPARATOR
Intervention: Epidermal growth factor, applied topically four times a day on the day of surgery and twice a day for two days thereafter.
Number of subjects: 2
Study 6333182 — intervention group
Group type: COMPARATOR
Intervention: Epidermal growth factor, applied topically at half concentration eight times a day for four days beginning the day before surgery.
Number of subjects: 2
Study 31132578 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Sleep Regularity Index (SRI)
Number of subjects: 170
Study 31132578 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle
Number of subjects: 170
Study 31132578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep onset time
Number of subjects: 170
Study 31132578 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI
Number of subjects: 170
Study 31132578 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time
Number of subjects: 170
Study 29045997 — intervention group
Group type: EXPERIMENTAL
Intervention: CS and BIS monitoring
Number of subjects: 50
Study 29045997 — intervention group
Group type: COMPARATOR
Intervention: CS alone
Number of subjects: 50
Study 26092285 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based headache diary (i-diary)
Number of subjects: 488
Study 26092285 — intervention group
Group type: COMPARATOR
Intervention: Paper diary (p-diary)
Number of subjects: 488
Study 26092285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diary types
Number of subjects: 488
Study 25301457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 348689
Study 25301457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) in patients with MMRS <10
Number of subjects: 348689
Study 25301457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) in patients with MMRS ≥20
Number of subjects: 348689
Study 22469850 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate and glucosamine hydrochloride (combination therapy)
Number of subjects: 251
Study 22469850 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (alone)
Number of subjects: 251
Study 22469850 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine hydrochloride (alone)
Number of subjects: 251
Study 22469850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 20502471 — intervention group
Group type: EXPERIMENTAL
Intervention: Family dietary coaching
Number of subjects: 2026
Study 20502471 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting dietary changes
Number of subjects: 2026
Study 18595980 — intervention group
Group type: COMPARATOR
Intervention: Synbiotics (4 probiotic species: Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp shermanii) with 0.8 g of galactooligosaccharides, daily for 6 months after birth.
Number of subjects: 925
Study 18595980 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily for 6 months after birth.
Number of subjects: 925
Study 18595980 — intervention group
Group type: COMPARATOR
Intervention: Synbiotics (4 probiotic species)
Number of subjects: 925
Study 18595980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 925